Jackson Creek Investment Advisors LLC Has $1.40 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Jackson Creek Investment Advisors LLC lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 23.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,413 shares of the biopharmaceutical company's stock after selling 10,714 shares during the period. Jackson Creek Investment Advisors LLC's holdings in TG Therapeutics were worth $1,396,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of TGTX. Clearbridge Investments LLC bought a new position in TG Therapeutics in the 4th quarter worth $55,237,000. Raymond James Financial Inc. bought a new position in TG Therapeutics in the 4th quarter worth $14,508,000. Norges Bank bought a new position in TG Therapeutics in the 4th quarter worth $12,085,000. Penn Capital Management Company LLC bought a new position in TG Therapeutics in the 4th quarter worth $10,577,000. Finally, First Trust Advisors LP raised its holdings in TG Therapeutics by 871.7% in the 4th quarter. First Trust Advisors LP now owns 275,496 shares of the biopharmaceutical company's stock worth $8,292,000 after acquiring an additional 247,145 shares during the period. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Trading Down 0.6%

NASDAQ:TGTX traded down $0.23 during trading hours on Friday, hitting $38.96. The stock had a trading volume of 126,732 shares, compared to its average volume of 2,453,914. TG Therapeutics, Inc. has a one year low of $16.65 and a one year high of $46.48. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. The company has a market cap of $6.19 billion, a price-to-earnings ratio of 162.33 and a beta of 1.91. The business's 50 day moving average is $36.33 and its 200-day moving average is $35.46.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The business had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The business's revenue for the quarter was up 90.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.07) EPS. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the transaction, the director directly owned 228,816 shares of the company's stock, valued at $8,452,463.04. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.64% of the company's stock.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a report on Thursday, July 10th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.